COVID-19 vaccination-related [18F]FDG-avid lymph node in a patient with marginal zone B-cell lymphoma

Paulina Ziolkowska; Alicja Salyga; Monika Joks; Marek Ruchala; Rafał Czepczynski

doi:10.5603/NMR.a2023.0004

COVID-19 vaccination-related [18F]FDG-avid lymph node in a patient with marginal zone B-cell lymphoma

Nucl Med Rev Cent East Eur. 2023;26(0):52-53. doi: 10.5603/NMR.a2023.0004.

Authors

Paulina Ziolkowska¹, Alicja Salyga^{2

3}, Monika Joks⁴, Marek Ruchala², Rafał Czepczynski^{2

3}

Affiliations

¹ Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland. [email protected].
² Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
³ Department of Nuclear Medicine, Affidea, Poznan, Poland.
⁴ Department of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.

PMID: 38966958
DOI: 10.5603/NMR.a2023.0004

Abstract

The [18F]FDG PET/CT is a crucial tool in the diagnostic process and monitoring of neoplastic diseases. Currently, during the global program of vaccination against COVID-19 and the possibility of axillary lymphadenopathy after this injection, the correct interpretation of PET/CT images is vitally significant and may create some difficulties. We present a case of increased uptake of [18F]FDG in an axillary lymph node in a PET/CT scan performed 2 days after the Pfizer BioNTech COVID-19 vaccine in a 48-year-old patient newly diagnosed with marginal zone B-cell lymphoma.

Keywords: COVID-19; PET/CT; marginal zone B-cell lymphoma; staging; vaccination.